• Product name
  • Description
    Rabbit polyclonal to NALP1
  • Host species
  • Tested applications
    Suitable for: IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Guinea pig, Cow, Cat, Dog, Pig
  • Immunogen

    Synthetic peptide corresponding to a region within N terminal amino acids 323-372 (DTQEPRIVIL QGAAGIGKST LARQVKEAWG RGQLYGDRFQ HVFYFSCREL) of Human NALP1 (NP_001028225).

  • Positive control
    • NCI-H226 cell lysate. IHC-P: FFPE human cerebral cortex tissue sections.



Our Abpromise guarantee covers the use of ab98181 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 155 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.


  • Function
    Able to form cytoplasmic structures termed death effector filaments. Enhances APAF1 and cytochrome c-dependent activation of pro-caspase-9 and consecutive apoptosis. Stimulates apoptosis through activation of caspase-3. Involved in activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Binds ATP.
  • Tissue specificity
    Widely expressed. Isoform 1 and isoform 2 are expressed in peripheral blood leukocytes and chronic myelogenous leukemia cell line K-562, followed by thymus, spleen and heart. Also detected in brain, lung, placenta, small intestine, colon, kidney, liver, muscle, testis and epithelial cells. Absent from hematopoietic progenitor cells but expressed upon differentiation of cells into granulocytes and, to a lesser extent, monocytes. In peripheral blood cells, highest levels are found in T-lymphocytes, granulocytes and monocytes. Expression is significantly increased in bone marrow blast cells of some acute leukemia patients but not in solid tumors.
  • Involvement in disease
    Genetic variations in NLRP1 are associated with susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a pigmentary disorder of the skin characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. It is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.
    Genetic variations in NLRP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
  • Sequence similarities
    Belongs to the NLRP family.
    Contains 1 CARD domain.
    Contains 1 DAPIN domain.
    Contains 6 LRR (leucine-rich) repeats.
    Contains 1 NACHT domain.
  • Cellular localization
    Cytoplasm. Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CARD 7 antibody
    • CARD7 antibody
    • Caspase recruitment domain protein 7 antibody
    • Caspase recruitment domain-containing protein 7 antibody
    • CLR17.1 antibody
    • Death effector filament forming Ced 4 like apoptosis protein antibody
    • Death effector filament-forming ced-4-like apoptosis protein antibody
    • DEFCAP antibody
    • DEFCAP L/S antibody
    • DKFZp586O1822 antibody
    • KIAA0926 antibody
    • LRR and PYD domains-containing protein 1 antibody
    • NAC alpha/beta/gamma/delta antibody
    • NAC antibody
    • NACHT antibody
    • NACHT leucine rich repeat and PYD containing 1 antibody
    • NACHT leucine rich repeat and PYD pyrin domain containing 1 antibody
    • NACHT leucine rich repeat and pyrin domain containing 1 antibody
    • NACHT LRR and PYD containing protein 1 antibody
    • NALP 1 antibody
    • NALP1 antibody
    • NALP1_HUMAN antibody
    • NLR family pyrin domain containing 1 antibody
    • NLRP 1 antibody
    • NLRP1 antibody
    • NLRP1 protein antibody
    • Nucleotide binding domain and caspase recruitment domain antibody
    • Nucleotide binding oligomerization domain leucine rich repeat and pyrin domain containing 1 antibody
    • Nucleotide-binding domain and caspase recruitment domain antibody
    • PP 1044 antibody
    • PP1044 antibody
    see all


  • IHC image of NAPL1 staining in human cerebral cortex formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab98181, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • Anti-NALP1 antibody (ab98181) at 1 µg/ml (in 5% skim milk / PBS buffer) + NCI-H226 cell lysate at 10 µg

    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size: 155 kDa

    Gel concentration: 6-18%


This product has been referenced in:
  • Ge X  et al. The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury. Brain Res N/A:N/A (2018). ICC/IF . Read more (PubMed: 29886252) »
  • Liu S  et al. Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1ß via suppressing astroglial NALP1 inflammasome and JAK2-STAT3 signalling. Sci Rep 6:28956 (2016). IHC-Fr ; Mouse . Read more (PubMed: 27381056) »

See all 2 Publications for this product

Customer reviews and Q&As

Abcam has not validated the combination of species/application used in this Abreview.
Western blot
Mouse Cell lysate - whole cell (primary bone marrow derived macrophage)
Loading amount
20 µg
primary bone marrow derived macrophage
Gel Running Conditions
Reduced Denaturing (12)
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C

Abcam user community

Verified customer

Submitted Sep 07 2011


Sign up